Bonesupport Holding AB (publ) (STO:BONEX)
Sweden · Delayed Price · Currency is SEK | Market Cap | 20.54B +51.1% |
| Revenue (ttm) | 1.40B +25.2% |
| Net Income | 271.77M +78.9% |
| EPS | 4.08 +79.0% |
| Shares Out | 65.22M |
| PE Ratio | 77.22 |
| Forward PE | 43.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,643 |
| Open | 321.40 |
| Previous Close | 320.40 |
| Day's Range | 311.20 - 325.20 |
| 52-Week Range | 165.00 - 340.20 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 374.67 (+18.94%) |
| Earnings Date | Oct 22, 2026 |
About Bonesupport Holding AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; and CERAMENT V, an injectable ceramic bone gra... [Read more]
Financial Performance
In 2025, Bonesupport Holding AB's revenue was 1.17 billion, an increase of 30.70% compared to the previous year's 898.73 million. Earnings were 142.15 million, an increase of 6.28%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BONEX stock is "Strong Buy." The 12-month stock price target is kr 374.67, which is an increase of 18.94% from the latest price.
News
Bonesupport Holding AB Earnings Call Transcript: Q3 2026
Q3 sales grew 38% at constant FX, with a 34% adjusted operating margin and SEK 510.5 million in quarter-end cash. FY growth guidance of 33%–36% was reaffirmed as CMS reimbursement and clinical evidence supported continued market expansion.
Bonesupport Holding AB Quarterly report: Q3 2026
Bonesupport Holding AB has published its Q3 2026 quarterly earnings report on October 22, 2026.
Bonesupport Holding AB Slides: Q3 2026
Bonesupport Holding AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Bonesupport Holding AB Earnings Call Transcript: Q2 2026
Q2 2026 saw 30% sales growth at constant exchange rates, strong cash flow, and a 29% adjusted operating margin. U.S. and EUROW segments both delivered robust growth, with guidance for full-year sales growth set at 33%-36%. Key risks include hospital usage restrictions and regulatory timing.
Bonesupport Holding AB Quarterly report: Q2 2026
Bonesupport Holding AB has published its Q2 2026 quarterly earnings report on July 16, 2026.
Bonesupport Holding AB Slides: Q2 2026
Bonesupport Holding AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Bonesupport Holding AB Transcript: CMD 2026
The event outlined a segment-specific strategy, an upward revision of U.S. market potential, and robust clinical evidence supporting CERAMENT’s differentiation. Financials show strong growth, with significant investments planned for clinical studies and commercial expansion, especially in spine and arthroplasty.
Bonesupport Holding AB Press release: FY 2026
Bonesupport Holding AB issued a press release on May 26, 2026, disclosing material business information to investors.
Bonesupport Holding AB Slides: FY 2026
Bonesupport Holding AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 26, 2026.
Bonesupport Holding AB Earnings Call Transcript: Q1 2026
Net sales grew 31% at constant exchange rates, led by strong U.S. CERAMENT G adoption and robust cash flow. CMS proposed reimbursement changes and regulatory progress for CERAMENT V support future growth, while commercial investments are expected to drive continued margin improvement.
Bonesupport Holding AB Quarterly report: Q1 2026
Bonesupport Holding AB has published its Q1 2026 quarterly earnings report on April 22, 2026.
Bonesupport Holding AB Slides: Q1 2026
Bonesupport Holding AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 22, 2026.
Bonesupport Holding AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 22% reported sales growth (36% at constant FX), driven by strong U.S. CERAMENT G adoption and expansion into trauma centers. Guidance for 2026 targets at least 35% constant FX growth, with upside from potential CERAMENT V approval.
Bonesupport Holding AB Quarterly report: Q4 2025
Bonesupport Holding AB has published its Q4 2025 quarterly earnings report on February 24, 2026.
Bonesupport Holding AB Slides: Q4 2025
Bonesupport Holding AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 24, 2026.
Bonesupport Holding AB Annual report: Q4 2025
Bonesupport Holding AB has published its Q4 2025 annual report on February 24, 2026.